C201 phase 2 will study immuno-enhancer antibody GM102, targeting AMHRII as a single agent and in combination with Trifluridine/Tipiracil (Lonsurf®)
A First-In Human study of monoclonal antibody GM102 in patients with Anti-Müllerian-Hormone-Receptor II (AMHRII) positive gynecological cancers
GamaMabs Pharma to present at 2018 ASCO annual meeting results from the First-In-Human clinical study of GM102 in advanced gynecological cancers
Objective responses, good safety and evidence of stimulation of the immune system were observed with GM102 administered as a single agent in the dose-finding escalation part of the study
A first-in-human study of monoclonal antibody GM102 in patients with anti- Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers.
Abstract # 5542_Presented Monday, June 4, 2018
AACR 2018: GamaMabs Pharma to present new data on expression of Anti-Müllerian Hormone type II Receptor in non-gynecological cancers and on first ADC candidate targeting AMHRII
AMHRII expression and Antibody-Drug Conjugate preclinical data suggest potential broader applications for anti-AMHRII-based therapy
GamaMabs Pharma receives Orphan Drug Designation from US FDA for lead compound GM102
This designation has been awarded for the treatment of AMHR2-expressing ovarian cancers, exclusive of AMHR2-expressing fallopian tube cancers and primary peritoneal cancers
GamaMabs Pharma sees two peer-reviewed articles published in Oncotarget, detailing the anti-tumor activity of GM102/3C23K
First in class anti-AMHRII monoclonal antibody is currently completing early clinical phases in ovarian cancer
GamaMabs and MedImmune Enter Licensing Agreement to Develop Antibody Drug Conjugate Targeting Cancer
GamaMabs and MedImmune, the global biologics research and development arm of AstraZeneca, today announced they have entered into a licensing agreement under which GamaMabs will use MedImmune’s proprietary pyrrolobenzodiazepine (PBD) toxin and linker technology to research and produce an antibody-drug conjugate (ADC) as a potential cancer therapy.
The humanized anti-human AMHRII mAb 3C23K exerts an antitumor activity against human ovarian cancer through tumor associated macrophages
Oncotarget journal published an article on GamaMabs’GM102 antibody.
Houcine Bougherara, Fariba Némati, André Nicolas, Gérald Massonnet, Martine Pugnière, Charlotte Ngô, Marie-Aude Le Frère-Belda, Alexandra Leary, Jérôme Alexandre, Didier Meseure, Jean-Marc Barret, Isabelle Navarro-Teulon, André Pèlegrin, Sergio Roman-Roman, Jean-François Prost, Emmanuel Donnadieu1, and Didier Decaudin, (2017) The humanized anti-human AMHRII mAb 3C23K exerts an antitumor activity against human ovarian cancer through tumor associated macrophages, Oncotarget
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Pauline Estupina et al., Oncotarget February 2017
Oncotarget journal published an article on GamaMabs’12G4 antibody (3C23K precursor).
Pauline Estupina, Alexandre Fontayne, Jean-Marc Barret, Nathalie Kersual, Olivier Dubreuil, Marion Le Blay, Alexandre Pichard, Marta Jarlier, Martine Pugnière, Maëva Chauvin, Thierry Chardès, Jean-Pierre Pouget, Emmanuel Deshayes, Alexis Rossignol, Toufik Abache, Christophe de Romeuf, Aurélie Terrier, Lucie Verhaeghe, Christine Gaucher, Jean-François Prost, André Pèlegrin, Isabelle Navarro-Teulon, (2017) The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Oncotarget